• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

使用Ronapreve™抗体成功治疗一名高危慢性淋巴细胞白血病患者的持续性重症SARS-CoV-2感染。

Successful treatment of persistent and severe SARS-CoV-2 infection in a high-risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies.

作者信息

Seganfredo Fernanda Braga, Dias Ana Raquel, Santos Pedro R, Rebelo Marta, João Cristina, Mendes Dina, Carmo Eduarda

机构信息

Haematology Department Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG) Lisbon Portugal.

Haematology Department Hospital do Divino Espírito Santo de Ponta Delgada Ponta Delgada Portugal.

出版信息

Clin Case Rep. 2022 Nov 15;10(11):e6548. doi: 10.1002/ccr3.6548. eCollection 2022 Nov.

DOI:10.1002/ccr3.6548
PMID:36408087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9666912/
Abstract

Patients with lymphoproliferative diseases are at an increased risk of an incomplete immune response following vaccination or SARS-CoV-2 infection and might develop persistent viral infection and severe COVID-19 disease. We present a case of successful treatment of persistent and mechanical-ventilation-requiring SARS-CoV-2 infection in a del17 CLL patient using exogenous antibodies.

摘要

淋巴增殖性疾病患者在接种疫苗或感染SARS-CoV-2后发生免疫反应不完全的风险增加，可能会出现持续性病毒感染和严重的COVID-19疾病。我们报告了一例使用外源性抗体成功治疗一名17号染色体缺失的慢性淋巴细胞白血病（CLL）患者持续性SARS-CoV-2感染且需要机械通气的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/252e/9666912/108ed3cdfa3a/CCR3-10-e6548-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/252e/9666912/89d5be994da2/CCR3-10-e6548-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/252e/9666912/108ed3cdfa3a/CCR3-10-e6548-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/252e/9666912/89d5be994da2/CCR3-10-e6548-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/252e/9666912/108ed3cdfa3a/CCR3-10-e6548-g001.jpg

相似文献

1
Successful treatment of persistent and severe SARS-CoV-2 infection in a high-risk chronic lymphocytic leukemia patient using Ronapreve™ antibodies.使用Ronapreve™抗体成功治疗一名高危慢性淋巴细胞白血病患者的持续性重症SARS-CoV-2感染。
Clin Case Rep. 2022 Nov 15;10(11):e6548. doi: 10.1002/ccr3.6548. eCollection 2022 Nov.
2
Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab.病例报告：两名慢性淋巴细胞白血病患者出现持续的新冠病毒2型感染并伴有新冠后状况：卡西瑞单抗/伊德维单抗新出现的治疗作用
Front Oncol. 2022 Sep 30;12:945060. doi: 10.3389/fonc.2022.945060. eCollection 2022.
3
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.继发抗体缺陷患者中持续的 SARS-CoV-2 感染：使用 casirivimab 和 imdevimab（REGN-COV2）单克隆抗体联合治疗后成功清除。
Ann Clin Microbiol Antimicrob. 2021 Dec 30;20(1):85. doi: 10.1186/s12941-021-00491-2.
4
Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case.罗那普瑞韦（REGN-CoV；卡西瑞韦单抗和依德维单抗）采用反映治疗用例的实验设计，降低了K18-hACE2小鼠体内的病毒载量，并改变了对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）德尔塔变异株（B.1.617.2）的肺部反应。
Microbiol Spectr. 2024 Aug 6;12(8):e0391623. doi: 10.1128/spectrum.03916-23. Epub 2024 Jul 16.
5
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.SARS-CoV-2 中和单克隆抗体预防 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
6
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.卡西瑞维单抗和英地维单抗给药时间相对于mRNA-1273 COVID-19疫苗接种时间对疫苗诱导的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）中和抗体反应的影响：一项前瞻性、开放标签、2期随机对照试验。
Lancet Infect Dis. 2025 Jan;25(1):52-67. doi: 10.1016/S1473-3099(24)00421-3. Epub 2024 Sep 2.
7
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.Casirivimab 和 Imdevimab 治疗可降低病毒载量并改善具有非中和或边缘中和抗体的血清阳性住院 COVID-19 患者的临床结局。
mBio. 2022 Dec 20;13(6):e0169922. doi: 10.1128/mbio.01699-22. Epub 2022 Oct 18.
8
Casirivimab/Imdevimab: First Approval.卡司瑞韦单抗/伊德韦单抗：美国首次批准
Drugs. 2021 Nov;81(17):2047-2055. doi: 10.1007/s40265-021-01620-z.
9
Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.严重急性呼吸综合征冠状病毒 2 型流行期间的慢性淋巴细胞白血病。
Curr Oncol Rep. 2022 Feb;24(2):209-213. doi: 10.1007/s11912-022-01198-z. Epub 2022 Jan 21.
10
Casirivimab-imdevimab monoclonal antibody treatment for an immunocompromised patient with persistent SARS-CoV-2 infection: a case report.卡西瑞维单抗-英夫维单抗单克隆抗体治疗一名患有持续性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的免疫功能低下患者：病例报告
Commun Med (Lond). 2024 Jun 1;4(1):103. doi: 10.1038/s43856-024-00523-w.

引用本文的文献

1
Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the Omicron surge.奥密克戎变异株流行期间尼马瑞韦联合利托那韦治疗慢性淋巴细胞白血病患者的疗效。
Blood. 2023 May 4;141(18):2239-2244. doi: 10.1182/blood.2022019017.

本文引用的文献

1
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.COVID-19 严重程度和死亡率在 CLL 患者中的研究：国际 ERIC 和 Campus CLL 研究的更新。
Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1.
2
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.慢性淋巴细胞白血病患者的新冠病毒感染：连续患者 13 个月期间的临床结局和 B 细胞与 T 细胞免疫。
Leukemia. 2022 Feb;36(2):476-481. doi: 10.1038/s41375-021-01424-w. Epub 2021 Sep 25.
3
Ronapreve for prophylaxis and treatment of covid-19.
罗那普瑞韦用于预防和治疗新冠病毒病。
BMJ. 2021 Sep 2;374:n2136. doi: 10.1136/bmj.n2136.
4
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era.血液系统恶性肿瘤患者对2019冠状病毒病信使核糖核酸疫苗的反应欠佳：在后口罩时代需要保持警惕
Open Forum Infect Dis. 2021 Jun 30;8(7):ofab353. doi: 10.1093/ofid/ofab353. eCollection 2021 Jul.
5
Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.2019冠状病毒病大流行期间慢性淋巴细胞白血病患者的管理
Oncol Lett. 2021 Aug;22(2):636. doi: 10.3892/ol.2021.12897. Epub 2021 Jul 3.
6
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.2019冠状病毒病疫苗对慢性淋巴细胞白血病患者的疗效
Leukemia. 2021 Sep;35(9):2703-2705. doi: 10.1038/s41375-021-01270-w. Epub 2021 May 13.
7
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
8
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
9
Positive aspects, negative aspects and limitations of plasma therapy with special reference to COVID-19.血浆疗法的积极方面、消极方面和局限性，特别针对 COVID-19。
J Infect Public Health. 2020 Dec;13(12):1818-1822. doi: 10.1016/j.jiph.2020.08.011. Epub 2020 Sep 1.
10
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项多中心国际经验
Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965.